Trial Profile
A Phase 1 Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 30 Jan 2023
Price :
$35
*
At a glance
- Drugs Brigatinib (Primary) ; Midazolam
- Indications Non-small cell lung cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors ARIAD Pharmaceuticals; Takeda
- 29 Dec 2022 Results (n=10) assessing Drug-Drug Interaction Study Between Brigatinib and the CYP3A Substrate Midazolam in Patients With ALK-Positive or ROS1-Positive Solid Tumors published in the Journal of Clinical Pharmacology
- 19 May 2021 Status changed from active, no longer recruiting to completed.
- 11 May 2020 Planned End Date changed from 31 May 2021 to 18 May 2021.